HSR Waiting Period Expires for Biogen Acquisition of Apellis

summarizeSummary

Apellis Pharmaceuticals announced the expiration of the HSR waiting period, clearing a major regulatory hurdle for its acquisition by Biogen.

check_boxKey Events

• HSR Waiting Period Expired

  The required waiting period under the Hart-Scott-Rodino (HSR) Act for the tender offer and merger with Biogen expired at 11:59 p.m., Eastern Time on May 11, 2026.

• Key Regulatory Condition Met

  This expiration satisfies a critical regulatory condition for the acquisition, moving the transaction closer to completion by removing a significant antitrust hurdle.

auto_awesomeAnalysis

This amendment confirms that the Hart-Scott-Rodino (HSR) Act waiting period for Biogen's acquisition of Apellis Pharmaceuticals has expired. This satisfies a key regulatory condition for the tender offer and merger, significantly advancing the deal towards completion. The expiration of this waiting period removes a major regulatory hurdle, making the acquisition more certain.